Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Financing Activities (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Cash from Financing Activities data on record, last reported at $7.0 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 769.67% year-over-year to $7.0 million; the TTM value through Sep 2025 reached $14.2 million, down 29.86%, while the annual FY2024 figure was $13.0 million, 2.93% up from the prior year.
  • Cash from Financing Activities reached $7.0 million in Q3 2025 per GANX's latest filing, up from $2.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $42.0 million in Q1 2021 and bottomed at -$213795.0 in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $4.4 million, with a median of $778793.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: crashed 1925.72% in 2021, then soared 161115.26% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$9735.0 in 2021, then crashed by 121.69% to -$21582.0 in 2022, then surged by 44398.94% to $9.6 million in 2023, then crashed by 75.81% to $2.3 million in 2024, then skyrocketed by 204.08% to $7.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $7.0 million in Q3 2025, $2.5 million in Q2 2025, and $2.4 million in Q1 2025.